Advertisement
The Company's presentation will take place in the Henry Salon (5th Floor)at 12:00 p.m. EST. Dr. Guoqing Jiang, Tianyin's Chairman and CEO, Mr. AllenTang, assistant to the CEO, and Mr. Stewart Lor, a member of the Board ofDirectors, will be representing Tianyin at the conference and will beavailable for one-on-one meetings with analysts and investors throughout theday.
Advertisement
Management will discuss the Company's current product portfolio,development pipeline, research and development platform, recent financialhighlights and its long term growth strategy.
Participation is by invitation and registration is mandatory. For moreinformation on the conference contact your Rodman & Renshaw representative orvisit www.rodmanandrenshaw.com.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 33 modernized TCMs and 4 generic western medicines in the market,22 of which are listed in the highly selective National Medicine Catalog ofthe National Medical Insurance Program. Tianyin owns and operates two GMPmanufacturing facilities and an R&D platform supported by leading Chineseacademic institutions. The Company has a pipeline of 48 pharmaceuticalproducts pending approval. Tianyin has an extensive nationwide distributionnetwork throughout China with a sales force of 720 salespeople. Tianyin isheadquartered in Chengdu, Sichuan Province with two manufacturing facilitiesand a total of 1,384 employees. Tianyin achieved revenue of approximately$33.5 million and net income of approximately $6 million in FY2008 ending June30, 2008. For more information about Tianyin, please visithttp://www.tianyinpharma.com
Safe Harbor Statement
This Press Release contains or may contain forward looking statements andinformation that are based upon beliefs of and information currently availableto the Company's management as well as estimates and assumptions made by theCompany's management. When used herein the words "anticipate", "believe","estimate", "expect", "future", "intend", "plan" and similar expressions asthey relate to the Company or the Company's management identify forwardlooking statements. These statements involve certain risks and uncertaintiesincluding but not limited to risks associated with the uncertainty of futurefinancial results, additional financing requirements, development of newproducts, government approval processes, the impact of competitive products orpricing, technological changes, the effect of economic conditions and otheruncertainties detailed in the Company's filings with the Securities andExchange Commission. Should one or more of these risks or uncertaintiesmaterialize, or should the underlying assumptions prove incorrect, actualresults may differ significantly from those anticipated, believed, estimated,intended or planned.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO China 15821225642 [email protected] Investors: HC International, Inc. Alan Sheinwald US (914) 669-0222 [email protected]
SOURCE Tianyin Pharmaceutical (TPI)
